Showing results (221-230 of 264) with videos related to

Sort By:
Pageof 27
Lancet (London, England)|March 24, 2026
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trialDavid J Thomson, James M Price, Matthew Tyler, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2020
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate CancerWilliam A Hall, Eric Paulson, Brian J Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Pageof 27